جستجوی استاد راهنمای دانشگاهی

• BRCA2 Protein
• Breast Neoplasms
• DNA Damage
• +۵ مورد دیگر

Ryan B. Jensen, PhD, is an Associate Professor at Yale School of Medicine with primary appointments in Therapeutic Radiology and secondary appointments in Pathology. He leads the Jensen Lab within the Yale Cancer Center and is a member of the DNA Damage and Genome Integrity Program. Dr. Jensen's research focuses on DNA double-strand break repair mechanisms, particularly the role of BRCA2 in homologous recombination. His lab employs a multi-disciplinary approach combining biochemistry, genetics, cell biology, structural biology, and proteomics to study how BRCA2 interacts with RAD51 and other proteins in DNA repair pathways. His recent publications (2019-2025) demonstrate a consistent research trajectory focused on BRCA2 function, RAD51-mediated DNA repair, and the molecular mechanisms underlying cancer development in DNA repair-deficient backgrounds. The lab has made significant contributions to understanding BRCA2's biochemical properties and how mutations affect its function. Dr. Jensen's work has significant implications for understanding cancer susceptibility and developing targeted therapies for BRCA-deficient cancers. His research on BRCA2 variants of uncertain significance bridges basic science with clinical applications in cancer risk assessment and treatment selection. BRCA2 Protein Function DNA Damage and Repair Mechanisms Homologous Recombination RAD51-Mediated Strand Exchange BRCA-Related Cancer Mechanisms PARP Inhibitor Sensitivity The Jensen Lab provides research opportunities for undergraduate and graduate students interested in DNA repair mechanisms and cancer biology. Current students include Jennifer Garbarino and Joshua Matthew. The lab has established collaborations with multiple researchers at Yale, including Peter M. Glazer, Ranjit S. Bindra, and Gemma Moore.

Stamatis Papathanasiouمشاهده پروفایل

استادیار

• Genomic Instability
• Mitosis
• Nuclear Architecture
• +۵ مورد دیگر

Dr. Stamatis Papathanasiou is a Group Leader at the Institute of Molecular Biology (IMB), Johannes Gutenberg University Mainz, where he directs a research team studying mitotic errors and genomic instability. He previously held a postdoctoral position at Harvard Medical School and Dana Farber Cancer Institute. His research examines how chromosome segregation errors lead to micronuclei formation, causing: DNA damage and chromothripsis Epigenetic alterations in MN-bodies Transcriptional heterogeneity affecting ageing and cancer The lab develops innovative methods like Look-Seq2 to link nuclear abnormalities to cellular dysfunction. Recent publications focus on CRISPR-induced genomic instability (2021-2023) and cardiac molecular biology (2015-2016), demonstrating interdisciplinary expertise in: Nuclear architecture dynamics Heritable transcriptional defects Genome editing consequences Cytoskeletal pathology

Peter Nelsonمشاهده پروفایل

استاد

• Prostate Cancer
• Cancer Genomics
• Androgen Receptor Pathway
• +۴ مورد دیگر

Peter Nelson, MD is a prominent Professor at Fred Hutchinson Cancer Research Center with multiple appointments across divisions including Human Biology, Clinical Research, and Public Health Sciences. He serves as Vice President of Precision Oncology and Director of the Stuart and Molly Sloan Precision Oncology Institute at Fred Hutch. Additionally, he holds a Professor position in Medical Oncology at the University of Washington School of Medicine and is an Adjunct Professor in Genome Sciences and Pathology. Vice President, Precision Oncology, Fred Hutch Director, Stuart and Molly Sloan Precision Oncology Institute Professor, Human Biology Division Stuart and Molly Sloan Precision Oncology Institute Endowed Chair Professor, Clinical Research Division Professor, Public Health Sciences Division Professor, Medical Oncology, University of Washington Genitourinary Oncology Clinical Research Director Adjunct Professor, Genome Sciences and Pathology Principal Investigator, Pacific Northwest Prostate Cancer SPORE Dr. Nelson's research focuses on understanding the molecular mechanisms of prostate cancer initiation and progression. His work spans cancer genomics, hormonal carcinogenesis, tumor microenvironment, and precision oncology strategies. Specifically, he investigates gene expression variability, the androgen receptor pathway, tumor microenvironment interactions, and molecular subtypes of prostate cancer to develop diagnostic, prognostic, and therapeutic approaches. His lab has identified promising biomarker candidates that could differentiate aggressive from indolent prostate cancers. Analysis of Dr. Nelson's recent publications reveals a strong emphasis on molecular subtyping of prostate cancer, with particular focus on DNA repair defects (BRCA1/2, mismatch repair), androgen receptor signaling mechanisms, and the role of the tumor microenvironment in therapy resistance. His work bridges genomic discoveries with clinical applications, particularly in identifying biomarkers for targeted therapies and developing precision oncology approaches for personalized prostate cancer treatment. Stuart and Molly Sloan Precision Oncology Institute Endowed Chair Principal Investigator, Pacific Northwest Prostate Cancer SPORE Kuni Foundation award for adult oncology research ($7M) Leadership in TakePART-NW precision oncology research program Dr. Nelson leads the Nelson Lab which focuses on prostate cancer as a model for understanding cancer heterogeneity and developing personalized approaches to oncology care. His research spans multiple areas including precision oncology, androgen receptor signaling, tumor microenvironment, new therapeutics, and cancer predisposition. The lab utilizes unique models including patient-derived xenografts and organoids to identify synergistic drug combinations capable of producing complete responses in prostate cancer. Dr. Nelson also oversees the Pacific Northwest Prostate Cancer SPORE, a multicenter research consortium that has driven significant advances in prostate cancer understanding and treatment over the past 25 years.

Udai B Pandeyمشاهده پروفایل

استاد

• Neurodegenerative Diseases
• ALS Research
• Genetics
• +۴ مورد دیگر

Udai B Pandey serves as a Professor in the Department of Human Genetics at the University of Pittsburgh, where his research centers on molecular mechanisms of neurodegenerative diseases, particularly ALS pathogenesis. His work integrates genetic, cellular, and biochemical approaches to investigate RNA-binding protein dysfunction, nucleocytoplasmic transport defects, and proteostasis collapse in motor neuron degeneration. His educational trajectory includes: PhD in Medical Genetics (1999-2004) from Sanjay Gandhi Postgraduate Institute of Medical Sciences, India Postdoctoral fellowship (2004-2008) in Neurology at the University of Pennsylvania Medical Center under J. Paul Taylor Postdoctoral fellowship (2008-2009) in Developmental Neurobiology at St. Jude Children’s Research Hospital, Memphis TN Dr. Pandey's research program explores how mutations in genes like FUS, TDP-43, and NEK1 drive ALS through disruptions in stress granule dynamics, nuclear import machinery, and microtubule function. His laboratory employs Drosophila models, mammalian cell systems, and patient-derived iPSCs to dissect disease mechanisms, with recent emphasis on phase separation biology and high-throughput drug screening for autophagy modulators. This translational focus bridges fundamental discoveries to therapeutic development for neurodegenerative conditions. Analysis of his 15 most recent publications (2016-2023) reveals consistent investigation into ALS-related proteinopathies, with escalating exploration of phase separation phenomena and genetic modifiers like GEMIN5. His work demonstrates methodological evolution from Drosophila genetics to human iPSC models and structural biology approaches, while maintaining core focus on nucleocytoplasmic transport defects as a unifying ALS mechanism. Scientific recognition includes: Faculty of 1000 Biology 'Must Read Paper' selection (2007) for his Nature publication on HDAC6's role in neuroprotection Dr. Pandey actively mentors graduate students and postdoctoral fellows, as evidenced by trainee-first-author publications spanning molecular genetics and neurobiology. His research program is supported by NIH funding focused on ALS pathogenesis mechanisms, with recent projects examining WNK kinase signaling in cell volume regulation and GEMIN5's role in neurodevelopment. Collaborations span multiple institutions including St. Jude Children's Research Hospital and the University of Pennsylvania. His laboratory operates within the Rangos Research Building at UPMC, utilizing advanced imaging, molecular biology, and high-throughput screening platforms to investigate neurodegenerative disease mechanisms and identify therapeutic targets for ALS and related disorders.

Nyree Myattمشاهده پروفایل

مدرس

• Biochemistry
• Oncology
• Immunology
• +۳ مورد دیگر

Dr. Nyree Myatt is a Lecturer in Biochemistry at the Institute of Health Sciences Education within Queen Mary University of London's Faculty of Medicine and Dentistry, where she has taught since 2020. She serves as co-module lead for MET1, MET2, and DMG (Digestion, Metabolism and Growth) in the MBBS program, delivers biochemistry lectures, and acts as a Problem-Based Learning (PBL) tutor for first/second-year students. Her academic responsibilities include senior tutoring for Year 2 students, MEDPRO tutoring, principal internal examination for graduate entry programs, chairing the iBSc Pre-Hospital Medicine exam board, and serving as IHSE library representative. Her research spans biochemistry, oncology (uveal melanoma, Fanconi Anemia), virology (orf virus), and medical education. Prior research includes post-doctoral work at UCL's Institute of Ophthalmology (uveal melanoma) and St George’s Hospital Medical School (Fanconi Anemia). Educational research focuses on assessment methods and student support systems. Degrees include: BSc in Biochemistry & Pharmacology (Leeds University) MSc in Experimental Pathology (Dundee University) PhD in Cytokine mRNA Expression (University of Edinburgh) PGCE (Greenwich University) Her 15 most recent publications demonstrate evolving research foci: early work (1994-2004) centered on ocular oncology and virology mechanisms, while recent outputs (2020-2023) transition to medical education innovation. Awards include no listed scientific honors. Teaching and student support includes developing interventions for repeating medical students and implementing online proctoring systems. No specific research grants or laboratory affiliations are detailed.

Friedhelm Hildebrandtمشاهده پروفایل

استاد

• Pediatric Nephrology
• Genetic Kidney Diseases
• Recessive Single-Gene Disorders
• +۷ مورد دیگر

Friedhelm Hildebrandt is a Professor of Pediatrics and Ophthalmology at Harvard Medical School and a leading researcher in pediatric nephrology at Boston Children's Hospital. As an investigator of the Howard Hughes Medical Institute (HHMI), he directs a highly productive research laboratory focused on identifying the genetic causes of kidney diseases in children. His work bridges basic science and clinical applications, with a particular emphasis on translating genetic discoveries into improved diagnostics and potential treatments. Dr. Hildebrandt received his MD from Marburg University Medical School and completed internships and residency at Marburg University Medical School and Heidelberg University in Germany, as well as Middlesex Hospital Medical School in London. He furthered his training with postdoctoral research at Yale University. His educational background has provided a strong foundation for his career in both clinical medicine and research. His research primarily focuses on the identification and functional characterization of recessive single-gene causes of kidney diseases in children. His laboratory has identified more than 30 novel kidney disease genes, significantly advancing our understanding of genetic kidney disorders. He has developed efficient methods for gene identification using whole exome resequencing and other highly-parallel sequencing techniques. Since 2000, Dr. Hildebrandt has performed 'experimental' mutation analysis in single-gene renal diseases worldwide for more than 5,000 pediatric patients, establishing himself as a global authority in the field. Analysis of his recent publications reveals a consistent focus on identifying novel genetic causes of kidney diseases, with particular emphasis on congenital anomalies of the kidney and urinary tract (CAKUT) and steroid-resistant nephrotic syndrome. His work increasingly incorporates advanced genomic techniques like trio exome sequencing and copy number variant analysis, while also exploring the functional consequences of genetic variants through animal models and molecular studies. A notable trend is the growing emphasis on translating genetic findings into potential therapeutic approaches, as evidenced by studies examining treatment response to anti-proteinuric therapies based on genetic profiles. E. Mead Johnson Award in Pediatric Research (APS/SPR) Howard Hughes Medical Institute (HHMI) Investigator Member of the American Association of Physicians (AAP) Member of the German Academy of Sciences (Leopoldina) Dr. Hildebrandt has secured substantial research funding to support his investigations into the genetic basis of pediatric kidney diseases. His laboratory serves as a training ground for numerous postdoctoral fellows and graduate students, many of whom have gone on to establish independent research careers. The lab maintains active collaborations with researchers worldwide, facilitating the identification of rare genetic variants through international patient cohorts. His work has established critical connections between DNA damage repair pathways and chronic kidney failure, opening new avenues for potential therapeutic interventions. Current research directions include developing quantitative phenotyping methods for animal models to support gene replacement studies and exploring the potential for genotype-guided treatments for children with genetic kidney diseases.

• Genetics
• Reproductive Biology
• Chromosome Biology
• +۵ مورد دیگر

Jennifer Rose Gruhn is an Assistant Professor in the Department of Cellular and Molecular Medicine at the University of Copenhagen, working within the Molecular Aging Program. She is an active member of the Hoffmann Group, where she conducts research at the intersection of reproductive biology, chromosome dynamics, and aging. Dr. Gruhn's research focuses on understanding the fundamental mechanisms of human reproduction, particularly the high error rates in chromosome segregation during egg development. Her work addresses why human reproduction is particularly error-prone, with 50% of pre-implantation embryos showing developmental defects and 20%-85% of human eggs exhibiting aneuploidy (extra or missing chromosomes). Maternal age is identified as the strongest risk factor for aneuploidy, making reproductive aging a central focus of her investigations. Her recent publications reveal a consistent research trajectory examining the molecular basis of chromosomal abnormalities in human reproduction. Studies span from basic mechanisms of DNA repair and chromosome recombination to clinical applications in pregnancy loss diagnostics. Her work combines model organisms (mouse and yeast) with human egg and embryo research to investigate the DNA damage response and cell cycle proteins governing genetic changes in the germline. Dr. Gruhn has been involved in significant collaborative efforts, including the Copenhagen Pregnancy Loss Study (COPL), which has generated high-impact publications in journals like Nature and The Lancet. Her research has garnered substantial attention, with multiple papers picked up by news outlets, blogged about, and widely shared on social media platforms. As part of the Hoffmann Group, Dr. Gruhn contributes to advancing our understanding of the genetic changes that occur during human reproduction, with implications for both reproductive health and cancer research, as many of the same genes involved in maintaining germline genome stability are also implicated in oncogenesis.

• Molecular Oncology
• Cholangiocarcinoma Research
• Cancer Epigenetics
• +۳ مورد دیگر

Juan Francisco Lafuente Barquero serves as an Assistant Professor in the Andersen Group at the Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen. His research focuses on the molecular mechanisms underlying biliary tract cancers, particularly cholangiocarcinoma and gallbladder cancer, with emphasis on genome instability, epigenetic regulation, and tumor microenvironment dynamics. His research interests span molecular oncology with specific focus on cancer epigenetics , genome instability mechanisms , cholangiocarcinoma pathogenesis , and tumor microenvironment interactions . His work integrates molecular biology, genomics, and cell biology approaches to understand the fundamental processes driving biliary tract cancers, with particular attention to transcription-associated genome instability, cytoskeletal dynamics in malignant transformation, and epigenetic remodeling during cancer progression. Analysis of his publication record reveals consistent contributions to high-impact hepatology and oncology journals including Journal of Hepatology , Trends in Cancer , and Molecular Genetics and Genomics . His research demonstrates evolving focus from fundamental genome stability mechanisms toward translational cancer biology, with increasing emphasis on molecular characterization of biliary tract cancers and identification of potential therapeutic targets. Recent work shows strong international collaboration networks spanning Europe and North America. No scientific awards were explicitly mentioned in the source material Dr. Lafuente Barquero actively collaborates within the Andersen Group led by Professor Jesper B. Andersen, contributing to multiple high-impact publications in liver cancer research. His work demonstrates significant grant-supported research activity through participation in international consortia including the CGR Exome Studies Group, with publications showing substantial citation impact (notably the 2020 Journal of Hepatology paper with 62 Scopus citations). While formal student mentorship isn't explicitly documented, his position as Assistant Professor suggests involvement in training graduate students and postdoctoral researchers within BRIC's academic environment. He operates within the Andersen Group at BRIC, a research environment focused on molecular cancer biology with particular expertise in liver cancers. The group maintains active collaborations with clinical researchers and international consortia, facilitating translational research from basic mechanisms to potential clinical applications in biliary tract cancers.

• Cancer Genomics
• DNA Repair
• Aging Research
• +۲ مورد دیگر

Simon Grund Sørensen is a Guest researcher at the Department of Cellular and Molecular Medicine within the Faculty of Health and Medical Sciences at the University of Copenhagen, affiliated with the Molecular Aging Program focused on molecular mechanisms of aging and age-related diseases. His research spans Cancer Genomics, DNA Repair, Aging Research, Molecular Biology, and Bioinformatics, investigating how DNA repair deficiencies drive characteristic mutational patterns across cancer types through genomic and computational approaches. This integrates molecular aging processes with cancer etiology to identify underlying genomic instability mechanisms. His 2023 eLife publication on pan-cancer DNA repair deficiencies exemplifies his work in genomic analysis, revealing how defective repair pathways generate mutation signatures across diverse cancers. This research bridges cancer genomics and aging biology by connecting DNA repair mechanisms to genome-wide mutational landscapes. No information is available regarding scientific awards, student advising, or research grants. Dr. Sørensen conducts research within the Molecular Aging Program, a collaborative initiative studying molecular aging pathways to develop interventions for age-related diseases like cancer.

• Cell Biology
• Genome stability
• DNA Damage Response
• +۲ مورد دیگر

Saskia Hoffmann is an Associate Professor at the Novo Nordisk Foundation Center for Protein Research (CPR) at the University of Copenhagen, where she leads research in the Mailand Group. She has held this position since October 2019 and maintains dual affiliation as both Associate Professor and Guest Researcher at CPR. Her academic credentials include: PhD in Biochemistry (2013-2016) from the University of Copenhagen, CPR, under Professor Niels Mailand with thesis on 'Functions of ubiquitin ligases in responses to replication stress and DNA damage' Master's in Biochemistry (2010-2012) from the University of Copenhagen supervised by Associate Professor Claus Storgaard Sørensen Bachelor's in Biochemistry (2007-2010) from the University of Leipzig, Germany, supervised by Professor Kurt Engeland Dr. Hoffmann's research program focuses on cellular responses to DNA damage and replication stress, with particular emphasis on understanding how cells counteract genotoxic insults to maintain genome stability. Her current work investigates the molecular link between human proteases and cellular surveillance pathways, revealing critical implications for human health and disease. Her research spans: Cell Biology mechanisms underlying genome maintenance Genome stability preservation pathways DNA Damage Response systems DNA Replication processes under stress conditions Protease functions in cellular surveillance Analysis of her publication record demonstrates a consistent research trajectory focused on DNA damage response mechanisms, protein modification systems (particularly ubiquitination and SUMOylation), and their roles in maintaining genome integrity. Her work frequently explores how defects in these pathways contribute to human diseases including genetic disorders and cancer, with several publications appearing in high-impact journals such as Nature Structural and Molecular Biology, Nature Communications, and Molecular Cell. Dr. Hoffmann has established herself as a significant contributor to the field of genome maintenance research, with her work on proteases and DNA damage response pathways opening new avenues for understanding disease mechanisms and potential therapeutic approaches.